Recent

% | $
Quotes you view appear here for quick access.

Star Scientific, AŞ Message Board

  • cigx1967 cigx1967 Sep 8, 2013 8:07 AM Flag

    all fees have been paid- we are close

    If protected what does this mean? I believe Big Pharma will become much friendlier to tiny little star, WHAT WILL THEY PAY

    Pharmaceutical compositions comprising an isolated form of a compound of Formula I or IA (e.g., anatabine or S-(-)-anatabine) or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low-level inflammation. Compounds of Formula I also can be provided, for example, in other vehicles such as beverage products and consumer products such as lotions and creams.
    Inventors: Williams; Jonnie R.; (Bradenton, FL)
    Assignee: ROCK CREEK PHARMACEUTICALS, INC.
    Gloucester
    MA

    Serial No.: 235860
    Series Code: 13
    Filed: September 19, 2011
    Current U.S. Class: 514/334
    Class at Publication: 514/334
    International Class: A61K 31/444 20060101 A61K031/444; A61P 37/00 20060101 A61P037/00; A61P 25/28 20060101 A61P025/28; A61P 35/00 20060101 A61P035/00; A61P 11/00 20060101 A61P011/00; A61P 25/16 20060101 A61P025/16; A61P 25/08 20060101 A61P025/08; A61P 25/00 20060101 A61P025/00; A61P 5/16 20060101 A61P005/16; A61P 3/10 20060101 A61P003/10; A61P 9/10 20060101 A61P009/10; A61P 29/00 20060101 A61P029/00; A61P 19/02 20060101 A61P019/02

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • CLAIMS-

      1. A method of reducing a symptom in an individual of a disorder comprising an NF.kappa.B-mediated inflammatory component, comprising administering to the individual a composition comprising a therapeutically effective dose of an isolated form of a compound of Formula I ##STR00005## wherein: R represents hydrogen or C.sub.1-C.sub.5 alkyl; R' represents hydrogen or C.sub.1-C.sub.7 alkyl; and X represents halogen or C.sub.1-C.sub.7 alkyl, or a salt thereof.

      2. The method of claim 1 wherein the compound is anatabine or S-(-)-anatabine.

      3. The method of claim 1 wherein the composition comprises a salt of anatabine or S-(-)-anatabine.

      4. The method of claim 1 wherein the NF.kappa.B-mediated inflammatory component is chronic inflammation.

      5. The method of claim 1 wherein the disorder is selected from the group consisting of an autoimmune disorder, a vascular inflammatory disorder, a gastrointestinal inflammatory disorder, a neurodegenerative disorder, cancer, an upper respiratory tract infection, a joint disorder, seizure disorder, and an autism spectrum disorder.

      6. The method of claim 5 wherein the disorder is an autoimmune disorder and the autoimmune disorder is selected from the group consisting of thyroiditis, rheumatoid arthritis, and diabetes.

      7. The method of claim 5 wherein the disorder is a vascular inflammatory disorder and the vascular inflammatory disorder is selected from the group consisting of atherosclerosis, coronary artery disease, cerebrovascular disease, peripheral vascular disease, and inflammation-induced myocarditis.

      8. The method of claim 5 wherein the disorder is a neurodegenerative disorder and the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease and Parkinson's disease, and wherein the compound of Formula I is S-(-)-anatabine.

      9. The method of claim 5 wherein the disorder is a cancer.

      10. The method of claim 5 wherein the disorder is an upper respiratory tract infection and the u

      • 1 Reply to cigx1967
      • CONTINUED-
        11. The method of claim 5 wherein the disorder is a joint disorder and the joint disorder is selected from the group consisting of osteoarthritis and degenerative joint disease.

        12. The method of claim 5 wherein the disorder is a seizure disorder or an autism spectrum disorder.

        13. The method of claim 1 wherein the dose is in an extended release formulation.

        14. The method of claim 1 wherein the dose is from about 0.1 to about 1.5 mg/kg body weight.

        15. The method of claim 1 further comprising administration of a second therapeutic agent.

        16. A method of reducing a risk in an individual of developing a disorder comprising an NF.kappa.B-mediated inflammatory component, comprising administering to the individual a composition comprising a therapeutically effective dose of an isolated form of a compound of Formula I or a salt thereof.

        17. A beverage product suitable for human consumption comprising a beverage container containing a liquid medium and an isolated form of a compound of Formula I ##STR00006## wherein: R represents hydrogen or C.sub.1-C.sub.5 alkyl; R' represents hydrogen or C.sub.1-C.sub.7 alkyl; and X represents halogen or C.sub.1-C.sub.7 alkyl, or a salt thereof.

        18. The beverage product of claim 17 wherein the compound is anatabine or S-(-)-anatabine.

        19. A consumer product selected from the group consisting of paste, cream, lotion, moisturizer, sunscreen, toothpaste, mouthwash, and an inhaler, wherein the product contains an isolated form of a compound of Formula I: ##STR00007## wherein: R represents hydrogen or C.sub.1-C.sub.5 alkyl; R' represents hydrogen or C.sub.1-C.sub.7 alkyl; and X represents halogen or C.sub.1-C.sub.7 alkyl, or a salt thereof.

        20. The consumer product of claim 19 wherein the compound is anatabine or S-(-)-anatabine.

 
STSI
0.00(0.00%)